CRISPR Therapeutics AG (CRSP) | Investment Case

1. Company Snapshot

1.a. Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA.The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies.In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases.

It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Show Full description

1.b. Last Insights on CRSP

Recent developments have bolstered CRISPR Therapeutics' prospects, driven by rising Casgevy sales and collaboration revenues from Vertex. The company's Q4 earnings report showcased a mature pipeline, with label expansion plans and updates forthcoming. Notably, Jones Financial Companies Lllp increased its stake by 50.2% during the third quarter, demonstrating institutional confidence. Additionally, the company's cash reserves and 60/40 global profit split with Vertex are expected to generate operating leverage and free cash flow as adoption and execution improve, according to a recent analysis by a financial expert.

1.c. Company Highlights

2013 - CRISPR Therapeutics AG was founded by Emmanuelle Charpentier, a French microbiologist, and Rodger Novak, a biotech entrepreneur.

2014 - CRISPR Therapeutics AG raised $25 million in Series A financing from investors, including New Enterprise Associates (NEA) and Versant Ventures.

2015 - CRISPR Therapeutics AG partnered with Vertex Pharmaceuticals to develop gene editing therapies for genetic diseases.

2016 - CRISPR Therapeutics AG raised $38 million in Series B financing from investors, including New Enterprise Associates (NEA) and Versant Ventures.

2018 - CRISPR Therapeutics AG went public with an initial public offering (IPO) and raised $56 million.

2019 - CRISPR Therapeutics AG and Vertex Pharmaceuticals announced positive results from a Phase 1/2 clinical trial of CTX001, a gene editing therapy for sickle cell disease and beta-thalassemia.

2020 - CRISPR Therapeutics AG and Vertex Pharmaceuticals announced that the FDA granted Fast Track designation to CTX001 for the treatment of sickle cell disease and beta-thalassemia.

Last Price	60.77
Change Percentage	1.05%
Open	58.04
Previous Close	60.14
Market Cap ( Millions)	5833
Volume	1330926
Year High	78.48
Year Low	30.04
M A 50	54.25
M A 200	54.88

FCF Yield	-5.93%
Dividend Yield	0.00%
ROE	-31.53%
Debt / Equity	20.55%
Net Debt / EBIDTA	-6.42%
Price To Book	2.84
Price Earnings Ratio	-9.4
Price To FCF	-16.86
Price To sales	2228.05
EV / EBITDA	-9.49

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?

Mar -02

Source: fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Mar -01

Source: fool.com

Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock

Feb -23

Source: defenseworld.net

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Feb -20

Source: fool.com

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices

Feb -20

Source: fool.com

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street

Feb -19

Source: fool.com

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Feb -19

Source: marketbeat.com

Crispr Therapeutics: Very High Risk But Even Higher Potential Reward

Feb -19

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.00%)

6. Segments

Collaboration

Expected Growth: 15.0%

CRISPR Therapeutics AG's 15.0% growth is driven by increasing adoption of gene editing technologies, strategic collaborations, and a strong pipeline of novel therapies. The company's pioneering CRISPR-Cas9 platform has attracted partnerships with leading biopharmaceutical companies, expanding its reach and accelerating innovation. Additionally, growing investments in research and development, and a favorable regulatory environment, contribute to the company's rapid growth.

Grant

Expected Growth: 14.43%

The 14.43% growth driven by CRISPR Therapeutics AG's grant is attributed to increasing adoption of gene editing technologies, strategic partnerships, and investments in research and development. Additionally, growing demand for novel therapeutic approaches and expanding applications in oncology, rare genetic diseases, and regenerative medicine contribute to the company's rapid growth.

7. Detailed Products

CRISPR-Cas9 Gene Editing

A precise genome editing tool that enables precise double-strand breaks in DNA, allowing for efficient and specific editing of genes

CRISPR-Cpf1 Gene Editing

A novel genome editing tool that offers improved efficiency and flexibility compared to CRISPR-Cas9, with potential applications in gene therapy and regenerative medicine

Allogenic CAR-T Cell Therapy

A type of immunotherapy that uses genetically modified T cells to target and kill cancer cells, with potential applications in treating various types of cancer

Autologous CAR-T Cell Therapy

A personalized immunotherapy approach that uses a patient's own T cells to target and kill cancer cells, with potential applications in treating various types of cancer

Gene-Edited Stem Cell Therapies

A novel approach that combines gene editing with stem cell therapy to treat genetic diseases and disorders

8. CRISPR Therapeutics AG's Porter Forces

Forces Ranking

Threat Of Substitutes

CRISPR Therapeutics AG has a low threat of substitutes due to its unique gene-editing technology, which is difficult to replicate.

Bargaining Power Of Customers

CRISPR Therapeutics AG has a medium bargaining power of customers, as it has a strong pipeline of products, but customers may have some bargaining power due to the competitive landscape.

Bargaining Power Of Suppliers

CRISPR Therapeutics AG has a low bargaining power of suppliers, as it has a strong supply chain and is not heavily reliant on a single supplier.

Threat Of New Entrants

CRISPR Therapeutics AG has a high threat of new entrants, as the gene-editing space is highly competitive and new companies are entering the market.

Intensity Of Rivalry

CRISPR Therapeutics AG operates in a highly competitive industry, with many established players and new entrants, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	11.25%
Debt Cost	3.95%
Equity Weight	88.75%
Equity Cost	12.91%
WACC	11.90%
Leverage	12.67%

11. Quality Control: CRISPR Therapeutics AG passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Genmab

A-Score: 5.8/10

Value: 3.2

Growth: 9.7

Quality: 9.5

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

Alkermes

A-Score: 5.0/10

Value: 4.9

Growth: 8.4

Quality: 8.9

Yield: 0.0

Momentum: 4.0

Volatility: 3.7

1-Year Total Return ->

Jazz Pharmaceuticals

A-Score: 4.9/10

Value: 4.8

Growth: 7.1

Quality: 4.7

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

Merus

A-Score: 3.5/10

Value: 6.0

Growth: 1.8

Quality: 3.4

Yield: 0.0

Momentum: 9.5

Volatility: 0.3

1-Year Total Return ->

Zealand Pharma

A-Score: 3.3/10

Value: 7.0

Growth: 2.2

Quality: 9.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

CRISPR Therapeutics

A-Score: 2.6/10

Value: 6.6

Growth: 1.1

Quality: 3.8

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

35.39%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

11.90%

CRISPR Therapeutics AG - CH0334081137

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on CRSP

1.c. Company Highlights

Medium Volatility

Average Yield

Fairly Valued

Earnings Beats

Revenues Miss

Earnings Miss

Lower Growth

Weak Momentum

Revenues Beats

Average Quality

More Volatile

Stable Momentum

Cheaper

Strong Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.00%)

6. Segments

Collaboration

Expected Growth: 15.0%

Grant

Expected Growth: 14.43%

7. Detailed Products

CRISPR-Cas9 Gene Editing

CRISPR-Cpf1 Gene Editing

Allogenic CAR-T Cell Therapy

Autologous CAR-T Cell Therapy

Gene-Edited Stem Cell Therapies

8. CRISPR Therapeutics AG's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: CRISPR Therapeutics AG passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

60.77$

Current Price

60.77$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA